Amendment No. 3 to Schedule 13D for PMV Pharmaceuticals, Inc.

OrbiMed Advisors LLC and OrbiMed Capital GP V LLC filed Amendment No. 3 to Schedule 13D, reporting a decrease in their beneficial ownership of PMV Pharmaceuticals, Inc. common stock by more than 1%. As of October 27, 2025, OrbiMed Private Investments V, LP (OPI V) holds 4,975,291 shares, representing approximately 9.4% of the outstanding shares. The decrease in ownership resulted from transactions where OPI V sold 500,000 shares on September 10, 2025, at $1.80 per share and 1,000,000 shares on October 23, 2025, at $1.52 per share. The filing also details the relationships between the reporting entities and their investment management authority over the shares held by OPI V. The amendment includes an Amended and Restated Investors' Rights Agreement, which outlines registration rights for the shares.